TrialThe Lancet. Oncology2012

First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Siow Ming Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.